参考文献:
[1]European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.
[2]Chinese Society of Hepatology,Chinese Medical Association,XU X, et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J].Hepatol Int, 2019, 13(1): 1-21.
[3]Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. (in Chinese)
中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425.
[4]YANG HR. Value of color Doppler ultrasound in the diagnosis of portal hypertension liver cirrhosis merged with esophageal variceal bleeding[J]. J Hainan Med Univ, 2016, 22(5): 496-498. (in Chinese)
杨海荣. 彩色多普勒超声在肝硬化门脉高压食管静脉曲张破裂出血中的价值[J]. 海南医学院学报, 2016, 22(5): 496-498.
[5]QI X, BERZIGOTTI A, CARDENAS A, et al. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension[J]. Lancet Gastroenterol Hepatol, 2018, 3(10): 708-719.
[6]de FRANCHIS R, DELL'ERA A, PRIMIGNANI M. Diagnosis and monitoring of portal hypertension[J]. Dig Liver Dis, 2008, 40(5): 312-317.
[7]HANNA RF, AGUIRRE DA, KASED N, et al. Cirrhosis-associated hepatocellular nodules: Correlation of histopathologic and MR imaging features[J]. Radiographics, 2008, 28(3): 747-769.
[8]PALANIYAPPAN N, COX E, BRADLEY C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol, 2016, 65(6): 1131-1139.
[9]MILLER L, BANSON FL, BAZIR K, et al. Risk of esophageal variceal bleeding based on endoscopic ultrasound evaluation of the sum of esophageal variceal cross-sectional surface area[J]. Am J Gastroenterol, 2003, 98(2): 454-459.
[10]LI S, ZHANG DF, LU W, et al. The predictive value of endoscopic ultrasound for the or the recurrence of esophageal varices after endo-scopic sophageal varix ligation[J]. Chin J Dis Endosc, 2016, 33(4): 223-228. (in chinese)
李爽, 张德发, 陆伟, 等. 超声内镜对食管静脉曲张套扎术后复发的预测作用[J]. 中华消化内镜杂志, 2016, 33(4): 223-228.
[11]MCCOLLOUGH CH, LENG S, YU L, et al. Dual- and multi-energy CT: Principles, technical approaches, and clinical applications[J]. Radiology, 2015, 276(3): 637-653.
[12]FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[13]Bureau of Medical Administration, National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese)
..国家卫生健康..医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292.
[14]VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462.
[15]RENZULLI M, BISELLI M, BROCCHI S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm[J]. Gut, 2018, 67(9): 1674-1682.
[16]MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma:2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-50.
[17]ZHOU XM, LIU CC, ZHOU W, et al. An excerpt of ACR appropriateness criteria chronic liver disease (2017) [J]. J Clin Hepatol, 2018, 34(1): 44-45. (in Chinese)
周新苗, 刘长春, 周巍, 等. 《2017年美国放射学会慢性肝病放射诊断的适用标准》摘译[J]. 临床肝胆病杂志, 2018, 34(1): 44-45.
[18]ROBERTS LR, SIRLIN CB, ZAIEM F, et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 401-421.
[19]PARK JW, KIM JH, KIM SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12): 1912-1921.
[20]LIN CY, CHEN JH, LIANG JA, et al. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis[J]. Eur J Radiol, 2012, 81(9): 2417-2422.
[21]BELLAARD R, DELGADO-BOLTON R, OYEN WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0[J]. Eur J Nucl Med Mol Imaging, 2015, 43(2): 328-354.
[22]NA SJ, OH JK, HYUN SH, et al. (18)-FDG PET/CT can prediat surival of advanced hepatocellular carcinoma patients: A multicenter retrospective cohort study[J]. J Nucl Mecl,2017, 58(5): 730-736.
[23]HECTORS SJ, WAGNER M, BESA C, et al. Multiparametric FDG-PET/MRI of hepatocellular carcinoma: Initial experience[J]. Contrast Media Mol Imaging, 2018, 2018: 5638283.
[24]MARGINI C, BERZIGOTTI A. Portal vein thrombosis: The role of imaging in the clinical setting[J]. Dig Liver Dis, 2017, 49(2): 113-120.
[25]SARIN SK, PHILIPS CA, KAMATH PS, et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis[J].Gastroenterology, 2016, 151(4): 574-577, e3.
[26]SHIMADA K, ISODA H, OKADA T, et al. Non-contrast-enhanced MR portography with time-spatial labeling inversion pulses: Comparison of imaging with three-dimensional half-fourier fast spin-echo and true steady-state free-precession sequences[J]. J Magn Reson Imaging, 2009, 29(5): 1140-1146.
[27]FURUTA A, ISODA H, YAMASHITA R, et al. Non-contrast-enhanced MR portography with balanced steady-state free-precession sequence and time-spatial labeling inversion pulses: Comparison of imaging with flow-in and flow-out methods[J]. J Magn Reson Imaging, 2014, 40(3): 583-587.
[28]OHNO T, ISODA H, FURUTA A, et al. Non-contrast-enhanced MR portography and hepatic venography with time-spatial labeling inversion pulses: Comparison at 1.5 Tesla and 3 Tesla[J]. Acta Radiol Open, 2015, 4(5): 2058460115584110.
[29]LYU Y, HAN GH, FAN DM. Research progress of portal vein thrombosis in patients with liver cirrhosis[J]. Chin J Dig , 2017, 37(8): 568-570.(in chinese)
吕勇, 韩国宏, 樊代明. 肝硬化门静脉血栓研究进展[J]. 中华消化杂志, 2017, 37(8): 568-570.
[30]SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: Outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
[31]LLOVET JM, PAVEL M, RIMOLA J, et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)[J]. Liver Transpl, 2018, 24(3): 369-379.
[32]SPOSITO C, CUCCHETTI A, MAZZAFERRO V. Assessing competing risks for death following liver transplantation for hepatocellular carcinoma[J]. Dig Dis Sci, 2019, 64(4): 1001-1007.
[33]ROSSANO G, MARTINA P, GIUSEPPE C, et al. Imaging of liver transplantation[J]. Eur J Radiol, 2017, 93: 295-307.
[34]GIROMETTI R, PANCOT M, COMO G, et al. Imaging of liver transplantation[J]. Eur J Radiol, 2017, 93: 295-307.
[35]RENNET J, DORNIA C, GEORGIEVA M, et al. Identification of early complications following liver transplantation using contrast enhanced ulrasound (CEUS), First results[J]. J Gastrointesti Liver Dis, 2012, 21: 407-412.
[36]WANG WP, HUANG BJ, DING H, et al. Preliminary application of contrast-enhanced ultrasound in detecting hepatic arterial embolization in liver transplantation [J]. Shanghai med imaging technol, 2006, 15(4): 272-273. (in Chinese)
王文平, 黄备建, 丁红, 等. 超声造影在检测移植肝肝动脉栓塞中的初步应用[J]. 上海医学影像技术, 2006, 15(4): 272-273.
[37]HWANG J, KIM YK, JEONG WK, et al. Nonhypervascular hypointense nodules at gadoxetic acid-enhanced MR imaging in chronic liver disease: Diffusion-weighted imaging for characterization[J]. Radiology, 2015, 276(1): 137-146.